An E1A / E1B double mutant oncolytic adenovirus expressing silencing PD-L1 gene and preparation method and application thereof

By constructing the E1A/E1B double mutant oncolytic adenovirus Ad-E1M-RGD-shPDL1 expressing the silencing PD-L1 gene, the problem of oncolytic adenovirus replication in normal cells and infecting tumor cells is solved, achieving high efficiency The anti-tumor effect and immune response significantly reduce the malignancy of tumor cells.

CN116064422BActive Publication Date: 2024-12-03HANGZHOU RANYU BIOMEDICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210792475.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-07
Publication Date
2024-12-03
Estimated Expiration
2042-07-07

AI Technical Summary

Technical Problem

The existing oncolytic adenovirus still replicates in normal cells to a certain extent, resulting in toxicity to normal cells and limited anti-tumor effects, especially in advanced or metastatic cancers, with low infection efficiency and high tumor cells. The expression of PD-L1 results in high malignancy, poor prognosis, and insufficient efficacy of existing immune checkpoint inhibitors.

Method used

Construct the E1A/E1B double mutant oncolytic adenovirus Ad-E1M-RGD-shPDL1 expressing the silenced PD-L1 gene, and the mutation was replaced by two amino acids at the binding site of E1A and Rb, E1B55KD deletion, and the cilia partial link RGD and E1A promoter. Inserting the shRNA of CD274 enhances the infection efficiency of tumor cells and reduces PD-L1 expression.

Benefits of technology

It maximizes the replication of viruses in normal cells, improves safety and anti-tumor effects, enhances the infection efficiency and immune response to tumor cells, significantly reduces the PD-L1 expression of tumor cells, and improves the prognosis of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116064422B_ABST
    Figure CN116064422B_ABST
Patent Text Reader

Abstract

The present invention discloses an E1A / E1B double mutant oncolytic adenovirus expressing a silent PD-L1 gene, and a preparation method and application thereof. The oncolytic adenovirus Ad-E1M-RGD-shPDL1 of the present application has both the deletion of E1B55KD and the mutation of the Rb binding site of E1A, eliminating the ability of the adenovirus to bind to p53 and Rb proteins, and can replicate in tumors with abnormal p53 function and / or abnormal Rb conduction pathways, while limiting its replication in normal cells, which is safer for normal cells. In addition, the RGD peptide chain is connected to the fiber part of the virus to establish integrin-dependent infection, which shows strong infection ability, replication ability and oncolytic effect on both CAR-negative and -positive cancer cells. PD-L1 shRNA is inserted into the viral E1A promoter to inhibit the expression of PD-L1 in tumor cells, thereby improving the anti-tumor immune effect and achieving a dual effect of oncolytic immunity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an E1A / E1B double mutant oncolytic adenovirus expressing a silent PD-L1 gene, and a preparation method and application thereof. Background Art

[0002] The incidence of cancer is increasing year by year. Early-stage cancer may be cured, but mid- and late-stage cancer is still incurable even with surgery, chemotherapy, molecular targeted drugs and immunotherapy, and new treatments need to be developed.

[0003] Oncolytic adenovirus can selectively replicate in tumor cells and destroy tumors while normal cells are not affected. It is considered to be a new type of anti-tumor drug. The theoretical basis for its tumor-selective replication is that the replication of adenovirus requires the cell cycle to enter the S phase. After the adenovirus infects the cell, its early protein E1A binds to the RB protein of the host cell, activates the E2F transcription factor, and forces the cell cycle to enter the S phase, thereby providing a good environment for the replication of the adenovirus. However, with the activation of E2F, p53 is also activated. The P53 protein blocks the cell cycle in the G1 phase or induces apoptosis, thereby limiting the replication of the virus. However, the E1B55KD protein of the adenovirus can bind to and inactivate the p53 protein, ultimately causing the cell cycle to enter the S phase, thereby enabling the adenovirus to replicate in the host cell. Therefore, the adenovirus with E1B55KD deletion cannot bind to and inactivate the p53 protein, and therefore cannot replicate in cells with normal p53 function, such as normal cells, but can replicate in cells with abnormal p53 function, such as tumor cells. Oncolytic adenovirus infects cancer cells and replicates in large quantities inside them, causing the cancer cells to dissolve and release a large amount of virus. The released virus can then infect nearby tissue cells again, and this cycle is repeated. Each time the virus titer increases by thousands of times until the tumor is completely destroyed. This is considered to be a promising means of treating tumors.

[0004] In 1996, Bischoff et al. first reported that the E1B55KD-deficient oncolytic adenovirus dl1520 (also called ONYX-015) could selectively replicate and destroy tumor cells with p53 gene mutations, but could not replicate in normal cells. However, the clinical trial of ONYX-015 for the treatment of head and neck cancer was terminated due to lack of clinical benefit. Chinese scholars constructed an oncolytic adenovirus Ankorui (H101: E1B 55KD deletion) similar to ONYX-015 for the treatment of head and neck squamous cell carcinoma, which showed a satisfactory objective response rate. Ankorui was approved for marketing by my country's Food and Drug Administration in 2005. It is the world's first oncolytic virus to be marketed. Since 2000, oncolytic adenoviruses dl922-947, Delta-24 (mutation of the E1A binding site to Rb eliminates the binding of the virus to cellular Rb) and CG0070 (embedded with the E2F promoter to target tumors with abnormal Rb) targeting tumors with abnormal Rb pathways have been reported internationally. The Phase II clinical trial of intravesical instillation of CG0070 for the treatment of non-muscle-invasive bladder cancer showed satisfactory efficacy, and Phase III clinical trials are currently underway. Phase I and II clinical trials of Delta-24-RGD (adenovirus linked to the RGD structure, which can enhance infection efficiency) for the treatment of brain gliomas are underway. Although oncolytic adenoviruses with single mutations in E1A or E1B have entered the clinical trial stage, studies have shown that adenoviruses with single mutations in E1A or E1B still replicate to a certain extent in normal cells, leading to toxicity to normal cells. In addition, immune checkpoint inhibitors are widely used in the treatment of malignant tumors, but their objective response rate is less than 30% when used alone, and most patients who respond do not show lasting remission after using immune checkpoint inhibitors, even if they are effective in the early stage. Existing antibody-based drugs work by conformationally blocking PD-L1 on the cell surface, but recent studies have shown that PD-L1 is not entirely present on the cell surface, but also exists inside the cell and can be refilled onto the cell membrane through circulation. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides an E1A / E1B double mutant oncolytic adenovirus expressing a silent PD-L1 gene, and a preparation method and application thereof.

[0006] The present application is implemented by adopting the following technical solutions.

[0007] The invention discloses an E1A / E1B double mutant oncolytic adenovirus that expresses a silencing PD-L1 gene, wherein the adenovirus E1A has two amino acid substitution mutations at the RB binding site, E1B55KD is deleted, the cilia part is linked to RGD, and the E1A promoter is inserted with shRNA of CD274.

[0008] The oncolytic adenovirus Ad-E1M-RGD-shPDL1 constructed in this application has mutations in the E1A and Rb binding sites, and a deletion in E1B55KD, which eliminates the ability of the virus to bind to the Rb and p53 proteins of normal cells, thereby limiting its replication in normal cells, thereby improving safety. Moreover, the E1A, E1B double mutant virus can replicate and destroy tumors in tumors with abnormal p53 conduction pathways and / or Rb conduction pathways, and has a wide anti-tumor spectrum. The oncolytic adenovirus Delta-24 deletes the CR-2 region and eliminates the ability to bind to host cell Rb, but its E1B55KD has not been modified, so it can bind to and inactivate p53 of normal cells, and cannot prevent cells from entering the S phase, thereby causing the virus to replicate in normal cells and destroy normal cells. Moreover, Delta-24 only replicates in tumor cells with abnormal Rb conduction pathways, but does not replicate in tumors without abnormal Rb conduction pathways, limiting its scope of application. Oncolytic adenoviruses ONYX-015 and Ankorui have deleted E1B55KD and cannot bind to and inactivate p53 in normal cells. Functional p53 can induce apoptosis. However, the E1A of these two viruses are wild-type and can bind to Rb of normal cells, release E2F, and promote cells to enter the S phase, thus providing a good environment for the replication of adenoviruses. The virus can replicate in normal cells. Moreover, these two viruses only replicate in tumors with abnormal p53 conduction pathways, but not in tumors with normal p53 conduction pathways, which also limits their scope of application.

[0009] Viral infection requires the virus to bind to the adenovirus receptor (CAR) on the host cell membrane in order to enter the cell. However, advanced or metastatic cancers lack CAR expression, and therefore resist viral infection, thereby reducing the oncolytic effect. However, the vast majority of tumors express integrins (αvβ3 or αvβ5), whose ligand is RGD. Therefore, the oncolytic adenovirus Ad-E1M-RGD-shPDL1 constructed in this application is linked to the RGD peptide chain in the viral fiber part. The virus does not rely on CAR, but directly binds to the integrin on the tumor surface, greatly improving the infection efficiency. However, Delta-24, ONYX-015, and Ankorui are not linked to RGD. These viruses have low infection efficiency for CAR-negative cancer cells, which greatly affects the infection efficiency and oncolytic effect.

[0010] Tumor cells that highly express PD-L1 have a high degree of malignancy and a poor prognosis, and reducing the expression of PD-L1 can reduce the malignancy of cancer cells and is expected to improve the prognosis of patients. In addition, one of the important reasons for tumor immune escape is the PD-L1 produced by tumor cells. Therefore, reducing the cellular abundance of PD-L1 is the key to reliable and persistent targeting of PD-L1 as a key immunosuppressive molecule. The oncolytic adenovirus Ad-E1M-RGD-shPDL1 constructed in this application carries a gene that silences PD-L1, which can reduce the expression of PD-L1 in tumor cells and is expected to enhance the body's anti-tumor immune effect. However, there are no reports of oncolytic adenoviruses expressing the silent PD-L1 gene.

[0011] When oncolytic viruses infect, replicate, and lyse tumor cells, they release tumor-specific antigens, thereby activating the body's specific immune response. Therefore, oncolytic viruses can kill tumor cells through both direct lysis and immune action. Oncolytic viruses can achieve a role similar to that of a "vaccine," promoting the presentation and recognition of tumor-associated antigens, and promoting circulating T cells to move to tumor sites for infiltration, thereby exerting an anti-tumor immune effect.

[0012] A method for constructing the above-mentioned E1A / E1B double mutant oncolytic adenovirus expressing the silencing PD-L1 gene comprises the following steps:

[0013] S1. Construction of pXC3E1A / E1B-shCD274 plasmid:

[0014] a. Constructing CD274 short hairpin RNA targeting human CD274145-165;

[0015] b. E1A (L122S / C124G) mutation and deletion of E1B-55KD;

[0016] c. Synthesize the full-length sequence of U6-shCD274-E1A promoter-E1A (L122S / C124G)-E1B (19K);

[0017] d. Insert U6-shCD274-E1A promoter-E1A (L122S / C124G)-E1B (19K) into the pXC3 shuttle plasmid;

[0018] S2. Construction of pBHG loxΔE1&E3Cre / RGD plasmid: E1 and E3 are deleted, and the plasmid links RGD-4C amino acids in the HI loop of the fiber part;

[0019] S3. pBHG loxΔE1&E3Cre / RGD was co-transfected with pXC3E1A / E1B-shCD274 into cells to produce oncolytic adenovirus Ad-E1M-RGD-shPDL1.

[0020] A use of the above-mentioned E1A / E1B double mutant oncolytic adenovirus expressing the silent PD-L1 gene in the preparation of tumor vaccines or anti-tumor drugs.

[0021] This application has the following beneficial effects.

[0022] 1. The oncolytic adenovirus Ad-E1M-RGD-shPDL1 of the present application is a double mutation of E1A and E1B, which limits the replication of the virus in normal cells to the maximum extent, greatly reduces the damage of the virus to normal cells, and improves safety; at the same time, the replication ability of the virus in tumor cells will not be reduced; the double mutant virus can replicate and destroy tumors in tumors with abnormal p53 conduction pathways and / or Rb conduction pathways, and has a broad anti-tumor spectrum;

[0023] 2. The oncolytic adenovirus Ad-E1M-RGD-shPDL1 of this application links RGD to establish integrin-dependent infection, thereby greatly improving the infection efficiency;

[0024] 3. The oncolytic adenovirus Ad-E1M-RGD-shPDL1 of the present application is inserted with shRNA that knocks out PD-L1, thereby reducing the expression of PD-L1 in tumor cells and enhancing the anti-tumor immune effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 is the plasmid map of the pXC3 vector of the present invention;

[0026] Figure 2 Is the plasmid map of the pXC1 vector of the present invention

[0027] Figure 3 This is the pBHG loxΔE1,3Cre plasmid map of the present invention;

[0028] Figure 4 is a structural diagram of the recombinant adenovirus of the present invention;

[0029] Figure 5 is a graph showing the relationship between the adenovirus Ad-E1M-RGD-shPDL1 of the present invention and the expression of cellular PD-L1;

[0030] Figure 6 This is a diagram showing the effect of the adenovirus Ad-E1M-RGD-shPDL1 of the present invention on the survival of a subcutaneous transplanted tumor model in mice. DETAILED DESCRIPTION

[0031] The present patent application is further described below in conjunction with the accompanying drawings and embodiments.

[0032] The CD274 short hairpin RNA targeting human CD274 (encoding PD-L) 145-165 is composed of the sense oligonucleotide 5'-ccggGACCTATATGTGGTAGAGTATctcgagCTCGAGATACTCTACCACATATAGGTCtttttg-3' (SEQ ID NO.1) and its related antisense oligonucleotide 5'-aattcaaaaaGACCTATATGTGGTAGAGTATctcgagCTCGAGATACTCTACCACATATAGGTC-3' (SEQ ID NO.2). The 21-nucleotide CD274 target sequence is represented by capital letters, while the hairpin sequence required for directional cloning is represented by lowercase letters. To construct pXC3E1A / E1B-shCD274, a short hairpin RNA with CD274, E1A(L122S / C124G) mutation, and E1B-55KD deletion E1A, E1B double-restricted adenovirus was generated, and the full-length sequence of U6-shCD274-E1A promoter-E1A(L122S / C124G)-E1B(19K) was spliced ​​from multiple plasmids by overlapping PCR. The specific amplification and splicing was divided into three parts. First, the U6-shRNA(CD274) promoter + target site was amplified, and then based on the pXC3 vector (Microbix Biosystems, Toronto, ON, Canada. As follows Figure 1 ), the promoter of E1A virus itself was constructed in pXC1 (Microbix Biosystems, Toronto, ON, Canada. as follows Figure 2 ), the E1A promoter + E1A gene was amplified, but this vector was E1A non-mutant, so an additional pair of primers was designed to mutate the CR2 region, and finally the three fragments were spliced ​​by overlapping PCR (Overlap PCR), and then the synthetic sequence was inserted into the pXC3 shuttle plasmid using Mlul and Hpal as restriction sites. The complete primers constructed and the identification information are as follows:

[0033] KL62293-P1 TACGGGCCAGATATACGGCTTTCGAGCGGCCGCCCCTCTCAC(SEQ ID NO.3)

[0034] KL62293-P2 CAGCAAACAAAGGCGTTAACCACACACGCAATCAC(SEQ ID NO.4)

[0035] KL62293-P3 AGGTCTTTTTGGGCCGCGGGGACTTTGACCGTTTAC(SEQ ID NO.5)

[0036] KL62293-P4

[0037] CCCGCGGCCCAAAAAGACCTATATGTGGTAGAGTATCTCGAGATACTCTACCACATATAGGTCCCGGTGTTTC(SEQ ID NO.6)

[0038] KL62293-P5 GATCGATAGTACTGGCCACGAGGCTGGCTTTCCACCCAG(SEQ ID NO.7)

[0039] KL62293-P6 CGTGGCCAGTACTATCGATCACCTCCGGTACAAGGTTTG(SEQ ID NO.8)

[0040] KL62293-W1F TATTATCTGCCACGGAGGTG (sequencing primer) (SEQ ID NO.9)

[0041] KL62293-W2R TCGTGAAGGGTAGGTGGTTC (sequencing primer) (SEQ ID NO.10)

[0042] KL62293-W3F AGGTCCTGTGTCTGAACCTG (sequencing primer) (SEQ ID NO.11)

[0043] KL62293-W4R CAAAACAGATACAAAACTAC (sequencing primer) (SEQ ID NO.12) construction process (GC 49.2%)

[0044] 1. Using PSC26784-1 as template (purchased from Shanghai Genetech, clone number PSC26784), and KL62293-P1 and KL62293-P4 as primers, PCR amplification was performed to obtain a 356 bp fragment a (amplification of U6-shRNA (CD274))

[0045] 2. Using pXC1 (KL20212) as a template (purchased from Shanghai Genetech, clone number KL20212), and using KL62293-P3 and KL62293-P6 as primers, PCR amplification was performed to obtain a 595 bp fragment b (amplified part of the E1A promoter and the E1A mutation part sequence)

[0046] 3. Using pXC1 (KL20212) as a template and KL62293-P5 and KL62293-P2 as primers, PCR amplification was performed to obtain a 676 bp fragment c (the sequence after the E1A mutation was amplified)

[0047] 4. Using a+b+c as template and KL62293-P1 and KL62293-P2 as primers, PCR amplification was performed to obtain a 1587 bp fragment d

[0048] 5. pXC3(KL20651-6) was digested with MluI and HpaI to obtain 3486bp+7.4kb, and the 7.4kb vector fragment V was recovered.

[0049] 6. Recombination: The full-length gene fragment obtained in step 4 is seamlessly cloned with the vector after enzyme cutting in step 5 using recombinase.

[0050] Positive identification: PCR identification was performed using KL62293-P5 and KL62293-W4R, and a band of 1411 bp was obtained for the positive transformants.

[0051] Positive sequencing: Use primers KL62293-W1F to KL62293-W4R.

[0052] After the shuttle plasmid was constructed, the packaging plasmid pBHG loxΔE1&E3Cre / RGD was constructed. The AdMax adenovirus packaging plasmid pBHG loxΔE1&E3 Cre established by Professor Frank L. Graham was used (see the plasmid map for details). Figure 3 )(Microbix.Canada, its sequence information can be found at http: / / www.microbix.com / Plasmid-Sequences / pBHGloxdeltaE13Cre.zip), which carries most of the adenovirus genome, but lacks E1 and E3. The RGD sequence was inserted into the pBHG loxΔE1&E3 Cre fiber part, and the process was as follows:

[0053] 1. Using pBHGloxΔE1&E3Cre as template and KL55430-P1 and KL55430-P4 as primers, PCR amplification was performed to obtain a 1926 bp fragment. The primer sequences are:

[0054] KL55430-P1: CATCAAGATCCTCTAGTTAATTAACTAGAGTACCCGGG (SEQ ID NO. 13);

[0055] KL55430-P4:

[0056] ACAGAAACAATCCCCCTGCAATCGCAAGTTGTGTCTCCTGTTTCCTGTGTAC (SEQ ID NO. 14).

[0057] 2. Using pBHGloxΔE1&E3Cre as template and KL55430-P3 and KL55430-P2 as primers, PCR amplification was performed to obtain a 4226 bp fragment. The primer sequences are:

[0058] KL55430-P3:

[0059] TGCGATTGCAGGGGGGGATTGTTTCTGTCCAAGTGCATACTCTATGTCATTTTC (SEQ ID NO. 15);

[0060] KL55430-P2: AGCCTCGTGGCAGGTAAGATCGATCACCTCCGGTACAAGG (SEQ ID NO. 16).

[0061] 3. Using 1926bp and 4226bp as templates and KL55430-P1 and KL55430-P2 as primers, PCR amplification was performed to obtain a 6125bp fragment. The primer sequences are:

[0062] KL55430-P1: CATCAAGATCCTCTAGTTAATTAACTAGAGTACCCGGG (SEQ ID NO. 13);

[0063] KL55430-P2: AGCCTCGTGGCAGGTAAGATCGATCACCTCCGGTACAAGG (SEQ ID NO. 16);

[0064] 4. Use PacI and ClaI to digest pBHGloxΔE1&E3Cre to obtain 6055bp+27.2kb, and recover the 27.2kb vector fragment

[0065] 5. Recombination: The full-length gene fragment obtained in step 3 and the vector after restriction digestion in step 4 were seamlessly cloned using a recombinase to obtain pBHGloxΔE1&E3(part)-RGD.

[0066] 6. PCR identification:

[0067] Identification primers:

[0068] KL55430-P5: GACTCCGGTGAGTTTTGCTAC (SEQ ID NO. 17);

[0069] KL55430-P6: AAACAATCCCCCCTGCAATC (SEQ ID NO. 18).

[0070] The size of the PCR product of the positive transformant: 2121

[0071] 7. Sequencing

[0072] The auxiliary packaging plasmid pBHG loxΔE1&E3Cre / RGD, which is missing E1 and E3, carries the RGD-4C amino acid in the HI loop of the fiber portion, which is located between amino acid residues 546 and 547. The amino acid sequence of the RGD mutation is as follows: T546CDCRGDCFCP547.

[0073] The auxiliary packaging plasmid pBHG loxΔE1&E3Cre / RGD and the shuttle plasmid pXC3E1A / E1B-shCD274 were co-transfected into 293 cells, and the Cre-loxP (or FLP / frt) recombinase cutting system was used to generate the recombinant oncolytic adenovirus Ad-E1M-RGD-shPDL1 carrying the exogenous gene (two amino acid substitution mutations at the E1A and RB binding sites, E1B55KD deletion, cilia partially linked to RGD, and E1A promoter inserted into CD274 shRNA) ( Figure 4 ). Adenoviral vectors were all packaged in HEK293 cells, then purified by CsCl density gradient centrifugation and stored at -80°C. Adenoviral titers were determined by standard plaque formation assay using HEK293 cells.

[0074] The specific experimental process is as follows:

[0075] (I) Overexpression adenoviral vector construction process

[0076] Gene name: gene(U6-shRNA(CD274)-E1Amut-E1B-19K)(SEQ ID NO.19)

[0077]

[0078] 1. Description of experimental materials

[0079] 1.1 Main Reagents

[0080]

[0081] 1.2 Main instruments

[0082]

[0083]

[0084] 2. Vector digestion

[0085] Vector information: Cloning site: MluI / HpaI

[0086] 3. Obtaining the target gene fragment

[0087] 3.1 Primers

[0088] SEQ ID NO name seq 3 KL62293-P1 TACGGGCCAGATATACGGCTTTCGAGCGGCCGCCCCTCTCAC 4 KL62293-P2 CAGCAAACAAAGGCGTTAACCACACACGCAATCAC

[0089] 3.2 PCR results

[0090] PCR product size: 1587 bp

[0091] 4. Recombinant plasmid construction

[0092] 4.1 Exchange of PCR products into linearized expression vector

[0093] 4.2 PCR identification results

[0094] Positive transformant PCR product size: 1411 bp

[0095] 4.3 Sequencing results and analysis of positive clones:

[0096] Comparison results:

[0097] AATTTCCGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTATACGGGCCAGATAT ACGCGT GTTAAC GCCTTTGTTTGCTGAATGAGTTGATGTAAGTTTAATAAAGGGTGAGATAATGTTTAACTTGCATGGCGTGTTAAATGGGGCGGGGCTTAAAGGGTATATAATGCGCCGTGGGCTAATCTTGGTTACATCTGACCTCATGGAG GCTTGGGAGTGTTTGGAAGATTTTTCTGCTGTGCGTAACTTGCTGGAACAGAGCTCTAACAGTACCTCTTGGTTTTGGAGGTTTCTGTGGGGCTCATCCCAGGCAAAGTTAGTCTGCAGAATTAAGGAGGATTACAAGT(SEQ ID NO.20)

[0098] 6. Plasmid Extraction

[0099] The correctly sequenced bacterial solution was transferred to 10 ml LB liquid culture medium containing corresponding antibiotics, cultured at 37°C overnight, and plasmids were extracted using Tiangen Endotoxin-Free Plasmid Mini-Extraction Kit. The qualified extracted plasmids entered the downstream process.

[0100] Gene name: pBHGloxdelE1&E3(part)-RGD

[0101] 1. Vector digestion

[0102] Vector information: Cloning site: PacI / ClaI

[0103] 2. Acquisition of target gene fragments

[0104] 2.1 Primers

[0105] SEQ ID NO name seq 13 KL 55430-P1 CATCAAGATCCTCTAGTTAATTAACTAGAGTACCCGGG 16 KL 55430-P2 AGCCTCGTGGCAGGTAAGATCGATCACCTCCGGTACAAGG

[0106] 2.2 PCR results

[0107] PCR product size: 6125

[0108] 3. Recombinant plasmid construction

[0109] 3.1 Product exchange into linearized expression vector

[0110] 3.2 PCR identification primers

[0111] SEQ ID NO ID seq 17 KL55430-P5 GACTCCGGTGAGTTTTGCTAC 18 KL55430-P6 AAACAATCCCCCCTGCAATC

[0112] 3.3 PCR identification of recombinant clones

[0113] The size of the PCR product of the positive transformant: 2121

[0114] 3.4 Sequencing

[0115] RGD sequence: bold, italic, and underlined parts

[0116]

[0117]

[0118]

[0119]

[0120]

[0121] (II) Adenovirus packaging and quality testing

[0122] 1. Experimental Materials

[0123] 1). Cell lines

[0124] HEK293 (ATCC, cat#CRL-1573) adenovirus packaging cells are anchorage-dependent epithelial cells, and the growth medium is DMEM medium containing 10% FBS. The cells contain and express the E1 region of Ad5 adenovirus, and E1-deficient adenovirus can grow in them.

[0125] 2).Strain

[0126] Escherichia coli strain DH5α is used to amplify adenoviral shuttle plasmids and auxiliary packaging vector plasmids.

[0127] 3). Plasmid

[0128] (1) Adenovirus shuttle plasmid: pXC3E1A / E1B-shCD274. The information is as described above.

[0129] (2) Auxiliary packaging plasmid: pBHG loxΔE1&E3Cre / RGD information is as described above.

[0130] 4). Reagents

[0131]

[0132] 5). Instruments

[0133]

[0134] 2. Plasmid transfection and adenovirus harvest

[0135] 1). 24 hours before transfection, use 0.25% trypsin to digest the HEK293 cells in the logarithmic growth phase, adjust the cell density to 30%-40% with DMEM medium containing 10% FBS, re-inoculate in a cell culture bottle, and culture in a 37°C, 5% CO2 incubator. When the cell density reaches 50%-60% in about 24 hours, it can be used for transfection;

[0136] 2). Change to serum-free medium 2 hours before transfection;

[0137] 3). Mix the DNA solution (5 μg of shuttle plasmid and 5 μg of auxiliary plasmid) with DMEM, adjust the total volume to 50 μl, and incubate at room temperature for 5 min; mix 10 μl of Lipofectamine 2000 reagent with 50 μl of DMEM, and incubate at room temperature for 5 min; gently mix the diluted DNA solution with Lipofectamine 2000 without shaking, and incubate at room temperature for 20 min to form a DNA / Lipofectamine 2000 transfection complex;

[0138] 4). Slowly add the transfection complex solution to the HEK293 cell culture medium, mix well, and culture in a 37°C, 5% CO2 cell culture incubator;

[0139] 5) After 6 hours of culture, discard the culture medium containing the transfection mixture, add 2 ml of PBS to wash once, shake gently to wash the remaining transfection mixture and then discard;

[0140] 6). Slowly add 5 ml of cell culture medium containing 10% serum, continue to culture in a 37°C, 5% CO2 incubator, and observe the cell growth after transfection every day. If the culture medium turns obviously yellow, add an appropriate amount of fresh complete culture medium as appropriate.

[0141] 7). About 10-15 days after transfection, observe the HEK 293 cells under a microscope to see if they begin to float and show cytopathic effect (CPE).

[0142] 8). When most cells show typical CPE and 50% of cells are detached from the cell wall, collect the cells by low-speed centrifugation and resuspend them in 2 ml DMEM. Repeat freezing and thawing at -70℃ / 37℃ and shaking for 3 times. Centrifuge at 4℃ and 7000g for 5 minutes, collect the virus supernatant and store it at -70℃.

[0143] 3. Adenovirus Amplification

[0144] 1). First round of amplification

[0145] HEK293 cells with good growth status were transferred into T25 cell culture flasks. When the cells reached 60% confluence, the old culture medium was discarded, 2 mL of crude adenovirus extract after successful recombinant was added, and the cells were placed in a cell culture incubator for 90 min, and then 3 mL of complete culture medium was added and cultured. When most cells showed typical CPE and 50% of the cells were detached from the wall, the cells were collected by low-speed centrifugation and resuspended in 2 ml DMEM, and repeatedly frozen and thawed at -70℃ / 37℃, shaken 3 times, and centrifuged at 4℃ and 7000g for 5 min. The virus supernatant was collected and stored at -70℃.

[0146] 2). Second round of amplification

[0147] HEK293 cells with good growth status were transferred into T25 cell culture flasks. When the cells reached 90% confluence, the old culture medium was discarded, and 2 ml of the virus solution obtained from the first round of amplification was added. After incubation in a cell culture incubator for 90 min, 10 ml of complete culture medium was added and culture was continued. When most cells showed typical CPE and 50% of the cells were detached from the wall, the cells were collected by low-speed centrifugation and resuspended in 10 ml DMEM, and repeatedly frozen and thawed at -70℃ / 37℃, shaken 3 times, centrifuged at 4℃ and 7000g for 5 min, and the virus supernatant was collected and stored at -70℃.

[0148] 4. Adenovirus Purification

[0149] Using Adeno-X TM Virus Purification Kit, BD Biosciences, Clontech.

[0150] 5. Adenovirus quality testing

[0151] The key points of adenovirus quality control include physical state testing, sterility testing and virus titer testing.

[0152] 1). Physical index detection

[0153] (1) pH value determination: The pH value range of the adenovirus storage solution developed by GeneCare is between 6.4 and 7.0;

[0154] (2) Determination of viscosity: Use a 20-200 μl gauge pipette to slowly aspirate 50 μl of adenovirus storage liquid. There should be no obvious viscosity or aspiration lag.

[0155] 2). Sterility testing

[0156] The virus was added to HEK293 cells for verification. After 24 hours of normal culture, microscopic examination showed no bacterial or fungal contamination. At the same time, referring to the empty cell group, there were no obvious particles in the intercellular space and the culture medium was clear and transparent.

[0157] 3). Adenovirus titer determination - endpoint dilution method

[0158] (1) 24 h before the experiment, a 96-well plate was plated and 100 μl of HEK293 cell suspension (containing approximately 1×10 3 cells;

[0159] (2) Prepare 12 sterile EP tubes. Add 990 μl of complete culture medium to the first EP tube and 900 μl of complete culture medium to each of the remaining 11 EP tubes.

[0160] (3) Dilution of the virus solution to be tested: Take 10 μl of the adenovirus stock solution and add it to the first EP tube for a 1:100 dilution; then use this as a starting point and add 100 μl of the virus dilution solution to the next EP tube for a 1:10 dilution until the dilution reaches 10. -13 .

[0161] (4) Discard the old culture medium in the 96-well plate and add 10 -13 Up to 10 -6 Each well of the first 10 wells in each row was added with 90 μl of virus dilution, and the 11th to 12th wells were added with 90 μl of complete culture medium without virus as a control.

[0162] (5) Place the 96-well plate in a 37°C, 5% CO2 cell culture incubator and continue culturing.

[0163] (6) After 10 days, observe the cell pathological phenomenon and count the cell wells showing CPE. Calculate the CPE positive rate after treatment with virus solution of each dilution and calculate the virus titer.

[0164] Virus titer analysis (Spearman-Karber Method):

[0165] Virus titer = 10 (x+0.8) (PFU / ml)*

[0166] X——10 -1 to 10 -13 The sum of CPE positive rates at different dilutions

[0167] *Formula usage conditions:

[0168] A Negative control showed no CPE and growth inhibition;

[0169] B. All wells to which the crude virus extract at the minimum dilution concentration was added showed CPE.

[0170] The virus titer of the sample in this application = 1×10 11 (PFU / ml)

[0171] (III) Performance testing of oncolytic adenovirus Ad-E1M-RGD-shPDL1

[0172] 1. The constructed Ad-E1M-RGD-shPDL1 infected human bladder cancer cell lines and reduced the expression of cellular PD-L1

[0173] Take cells in logarithmic growth phase, scrape off the cells with a scraper, centrifuge at 1000rpm for 5min, add RIPA lysis solution containing PMSF with 5 times the volume of cells, mix well and place on ice for lysis for 15-20 minutes, shake the EP tube every 5-10 minutes to make the protein lysis complete, and centrifuge at 12000rpm at 4℃ for 15 minutes after lysis. After centrifugation, take the supernatant, that is, the protein solution, which can be stored in a -20℃ refrigerator after aliquoting. Use the BCA protein quantification kit to determine the total protein concentration of the cells, and dilute the standard sample according to the actual instructions to set up 6 concentration gradients. Add 200μl BCA working solution to each well, add 25μL of the diluted BSA standard of different concentrations and the protein sample to be tested (diluted) to a 96-well plate, and each sample can be reacted in 2-3 parallel reactions. Incubate at 37℃ for 30 minutes, cool to room temperature, and use an enzyme reader to measure the absorbance of each sample at 562nm, and calculate the protein concentration of the sample after drawing a standard curve. The molecular weight of the protein PD-L1 detected in this experiment is between 30-70kd. A 4-20% gradient Bis-Tris precast gel (GenScript SurePAGE, CatNo.M00657) is used. The precast gel is fixed on the electrophoresis device and sufficient electrophoresis buffer is added. Take an appropriate amount of protein solution and add PBS to dilute the protein concentration to 1mmol / L, add loading buffer at 1:5, boil for 5 minutes to denature the protein, design the loading sequence and record it, and add 20μL of loading to each well. Connect the electrophoresis device, constant voltage 100-120V, 60 minutes, stop electrophoresis when bromophenol blue reaches the bottom. Soak the PVDF membrane in methanol for 20 seconds to activate it, and then soak it in 1× transfer solution for standby use. Take the required separation gel part and put it into the transfer solution, prepare the transfer splint, put the sponge, filter paper, and separation gel on the black splint in turn to prepare a transfer "sandwich", and transfer the membrane at a current of 200mA for 1 hour. The blocking solution was 5% skim milk powder prepared in TBST, and the PVDF membrane was taken out and blocked for 1 hour.

[0174] Dilute the primary antibody with TBST, dilute rabbit anti-human GAPDH monoclonal antibody (Proteintech, Cat No. 10494-1-AP) at 1:5000, dilute rabbit anti-human PD-L1 monoclonal antibody (Proteintech, Cat No. 17952-1-AP) at 1:1000, and incubate at 4°C overnight. Rinse with 1× TBST for 10 min × 3 times, add 1:1000 diluted HRP-labeled rabbit antibody and incubate at room temperature for 1 hour. Rinse with 1× TBST 3 times, 10 minutes each time, mix the ECL color reagent, and put it in the developer for development.

[0175] Western blotting was used to detect the expression of PD-L1 after Ad-E1M-RGD-shPDL1 infected bladder cancer cell lines (YTS-1, T24). The results showed that after Ad-E1M-RGD-shPDL1 infected bladder cancer cell lines, the expression of PD-L1 in bladder cancer cells was significantly decreased (MOI = 30) ( Figure 5 ).

[0176] 2. Detection of the effect of Ad-E1M-RGD-shPDL1 on the survival of subcutaneous transplanted tumor models in mice

[0177] 6-week-old NSG mice were supplied by Hangzhou Hangsi Biotechnology Co., Ltd. The mice were raised in the Animal Experiment Center of Zhejiang Cancer Hospital, with 6 mice per cage and cages changed once a week. The experiment was started after one week of breeding. The human invasive bladder cancer cell line YTS-1 (provided by Tohoku University, Japan, and preserved by the Institute of this hospital) was used. The cells were cultured in RPMI1640 medium containing 10% FBS (fetal bovine serum) at 75 cm 2 The cells were cultured in a culture flask, and when the cells grew to 90%, the cells were inoculated into mice. During the experiment, the culture medium of the culture flask was removed, and PBS (5 ml / flask) was added to the culture flask. The cells were scraped off with a sterile cell scraper, and the cell fluid was collected and placed in a centrifuge tube for centrifugation at 1200 rpm for 3 minutes. The supernatant was discarded, and PBS was added to resuspend the cells so that each 100 ul contained 5×10 6 cells. Place the cells in a box filled with ice chips, use 20 1ml syringes to extract 100ul of cell fluid and place in an ice box for later use (one tube for each mouse). Prepare the mouse skin in advance, shave the hair on the right hip of the mouse, disinfect the skin with 70% alcohol, and inject 100ul of cell fluid subcutaneously. Patrol the mouse activity status every day and observe the tumor growth. When the maximum size of the tumor reaches 5-6mm, inject the prepared PBMC (peripheral blood mononuclear cells) into the tumor, and inject 1×10 6PBMC (50ul). The preparation process of PBMC is as follows: draw blood from a healthy person and add it to an anticoagulant tube, take a 50ml centrifuge tube, add 15ml of normal saline, then add 15ml of blood, mix well, take another 50ml centrifuge tube, add 15ml of human peripheral blood lymphocyte separation solution (LTS077, Tianjin Haoyang), add the blood and normal saline mixture on top, centrifuge at 2400rpm for 15 minutes using a lifting centrifuge. Pipette the circular milky white lymphocyte layer into another 15ml centrifuge tube, add 10ml of normal saline, centrifuge at 1500rpm for 5 minutes, discard the supernatant, add cell culture medium to resuspend, and plant PBMC in a 6-well plate incubated with anti-human CD3 monoclonal antibody (BE0231, BioXcell). The 6-well plate was pre-treated as follows: 2ml of PBS containing anti-CD3 antibody was added to each well of the 6-well plate, and the concentration of anti-CD3 antibody was 3ug / ml, and incubated at 37 degrees for 2 hours. The liquid in the well plate was aspirated, and PBMC cell fluid was added to the 6-well plate and cultured at 37°C for 72 hours. During the experiment, PBMC cell fluid was collected, washed with PBS, centrifuged, resuspended in PBS, and the cells were counted. Each mouse was injected intratumorally with 1×10 6 PBMC cells, volume 50ul. On the second day after PBMC injection, mice were divided into groups, 6 in each group, and oncolytic adenovirus 1×10 8 pfu / mouse, the control group used the same amount of replication-deficient adenovirus, and the treatment group used Ad-E1M-RGD-shPDL1 intratumoral injection. The survival time of mice was observed. The results showed that the average survival time of mice in the treatment group was 17 days, while that in the control group was 14 days, with a significant difference between the two (P=0.0211)( Figure 6 ).

[0178] The embodiments of this specific implementation method are all preferred embodiments of the present invention, and are not intended to limit the protection scope of the present invention. Therefore, any equivalent changes made based on the structure, shape, and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for constructing an E1A / E1B double mutant oncolytic adenovirus expressing a silencing PD-L1 gene, characterized in that: The adenovirus has two amino acid substitution mutations at the E1A and RB binding sites, E1B55KD is deleted, the cilia part is linked to RGD, and the E1A promoter is inserted into the shRNA of CD274; the adenovirus has two amino acid substitution mutations at the E1A and RB binding sites to L122S / C124G; The construction method includes the following steps: S1. Construction of pXC3E1A / E1B-shCD274 plasmid: a. Construction of CD274 short hairpin RNA targeting human CD274145-165; amplification primers as shown in SEQ ID NO.3 and SEQ ID NO.6; b. E1A was mutated to L122S / C124G, and E1B-55KD was deleted; the amplification primers were as shown in SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.7, and SEQ ID NO.8; c. Synthesize the full-length sequence of U6-shCD274-E1A promoter-E1A-E1B 19KD. The sequence of U6-shCD274-E1A promoter-E1A-E1B 19KD is shown in SEQ ID NO.19; the amplification primers are shown in SEQ ID NO.3 and SEQ ID NO.4; d. Insert U6-shCD274-E1A promoter-E1A-E1B 19KD into pXC3 shuttle plasmid; S2. Construction of pBHG loxΔE1&E3Cre / RGD plasmid: E1 and E3 are deleted, and the RGD-4C amino acid is linked in the HI loop of the fiber part of the plasmid; the amplification primers are shown in SEQ ID NO.13-16; S3. pBHG loxΔE1&E3Cre / RGD was co-transfected with pXC3E1A / E1B-shCD274 into cells to produce oncolytic adenovirus Ad-E1M-RGD-shCD274.

2. Use of an E1A / E1B double mutant oncolytic adenovirus expressing a silenced PD-L1 gene constructed by the construction method of claim 1 in the preparation of a tumor vaccine or an anti-tumor drug.